These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26120082)

  • 1. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.
    Flaveny CA; Griffett K; El-Gendy Bel-D; Kazantzis M; Sengupta M; Amelio AL; Chatterjee A; Walker J; Solt LA; Kamenecka TM; Burris TP
    Cancer Cell; 2015 Jul; 28(1):42-56. PubMed ID: 26120082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are Synthetic Compounds that Silence the Liver-X-Receptor the Next Generation of Anti-cancer Drugs?
    Steffensen KR
    Cancer Cell; 2015 Jul; 28(1):3-4. PubMed ID: 26175408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer drugs: Repressing LXRs to starve cancer.
    Kingwell K
    Nat Rev Drug Discov; 2015 Sep; 14(9):602. PubMed ID: 26323542
    [No Abstract]   [Full Text] [Related]  

  • 4. Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis.
    Feng K; Ma C; Liu Y; Yang X; Yang Z; Chen Y; Xu T; Yang C; Zhang S; Li Q; Wei Z; Zhao D; Zeng P; Han J; Gao J; Chen Y; Duan Y
    Theranostics; 2021; 11(6):2634-2654. PubMed ID: 33456564
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
    Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
    J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
    Cannon MV; Yu H; Candido WM; Dokter MM; Lindstedt EL; Silljé HH; van Gilst WH; de Boer RA
    Eur J Heart Fail; 2015 Mar; 17(3):273-82. PubMed ID: 25684370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinnamamides, Novel Liver X Receptor Antagonists that Inhibit Ligand-Induced Lipogenesis and Fatty Liver.
    Sim WC; Kim DG; Lee KJ; Choi YJ; Choi YJ; Shin KJ; Jun DW; Park SJ; Park HJ; Kim J; Oh WK; Lee BH
    J Pharmacol Exp Ther; 2015 Dec; 355(3):362-9. PubMed ID: 26384859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma.
    Na TY; Shin YK; Roh KJ; Kang SA; Hong I; Oh SJ; Seong JK; Park CK; Choi YL; Lee MO
    Hepatology; 2009 Apr; 49(4):1122-31. PubMed ID: 19105208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors.
    Chen Z; Chen H; Zhang Z; Ding P; Yan X; Li Y; Zhang S; Gu Q; Zhou H; Xu J
    Eur J Med Chem; 2020 Nov; 206():112793. PubMed ID: 32961480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of new LXR modulators that regulate LXR target genes and reduce lipogenesis in human cell models.
    Høgmoen Åstrand OA; Gikling I; Sylte I; Rustan AC; Thoresen GH; Rongved P; Kase ET
    Eur J Med Chem; 2014 Mar; 74():258-63. PubMed ID: 24480357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).
    Li X; Yeh V; Molteni V
    Expert Opin Ther Pat; 2010 Apr; 20(4):535-62. PubMed ID: 20302451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-1 and microRNA-206 suppress LXRα-induced lipogenesis in hepatocytes.
    Zhong D; Huang G; Zhang Y; Zeng Y; Xu Z; Zhao Y; He X; He F
    Cell Signal; 2013 Jun; 25(6):1429-37. PubMed ID: 23499676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver X receptor modulators: a review of recently patented compounds (2009 - 2012).
    Loren J; Huang Z; Laffitte BA; Molteni V
    Expert Opin Ther Pat; 2013 Oct; 23(10):1317-35. PubMed ID: 23826715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes.
    Darimont C; Avanti O; Zbinden I; Leone-Vautravers P; Mansourian R; Giusti V; Macé K
    Biochimie; 2006; 88(3-4):309-18. PubMed ID: 16298468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hexane Fraction of cyperus rotundus Prevents Non-Alcoholic Fatty Liver Disease Through the Inhibition of Liver X Receptor α-Mediated Activation of Sterol Regulatory Element Binding Protein-1c.
    Oh GS; Yoon J; Lee GG; Kwak JH; Kim SW
    Am J Chin Med; 2015; 43(3):477-94. PubMed ID: 25967664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 20(S)-protopanaxatriol inhibits liver X receptor α-mediated expression of lipogenic genes in hepatocytes.
    Oh GS; Yoon J; Lee GG; Oh WK; Kim SW
    J Pharmacol Sci; 2015 Jun; 128(2):71-7. PubMed ID: 26109499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet.
    Uebanso T; Taketani Y; Yamamoto H; Amo K; Tanaka S; Arai H; Takei Y; Masuda M; Yamanaka-Okumura H; Takeda E
    J Nutr Biochem; 2012 Jul; 23(7):785-90. PubMed ID: 21889884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver X receptors regulate de novo lipogenesis in a tissue-specific manner in C57BL/6 female mice.
    Korach-André M; Archer A; Gabbi C; Barros RP; Pedrelli M; Steffensen KR; Pettersson AT; Laurencikiene J; Parini P; Gustafsson JÅ
    Am J Physiol Endocrinol Metab; 2011 Jul; 301(1):E210-22. PubMed ID: 21521718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice.
    Sheng X; Wang M; Lu M; Xi B; Sheng H; Zang YQ
    Am J Physiol Endocrinol Metab; 2011 May; 300(5):E886-93. PubMed ID: 21364120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
    Hussain A; Qazi AK; Mupparapu N; Guru SK; Kumar A; Sharma PR; Singh SK; Singh P; Dar MJ; Bharate SB; Zargar MA; Ahmed QN; Bhushan S; Vishwakarma RA; Hamid A
    Cancer Lett; 2016 May; 374(2):250-60. PubMed ID: 26921131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.